Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Aadi Bioscience, Inc logo — Aadi is a commercial-stage biopharmaceutical company focused...

Aadi Bioscience, Inc

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers.

Founded 2011 United States Los Angeles, United States 69 employees Post-IPO Equity Total: $250.50M Biopharma, Biotechnology +1

General Information

Company Name Aadi Bioscience, Inc
Founded Year 2011
Location United States Los Angeles, United States
Employees 69
Industries Biopharma, Biotechnology, Life Sciences
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Aadi Bioscience, Inc. To contact Aadi Bioscience, Inc, visit aadibio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Aadi Bioscience, Inc compare?

A PDF of Aadi Bioscience, Inc and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Aadi Bioscience, Inc soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Aadi Bioscience, Inc

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company with a focus on precision therapies for genetically-defined cancers. The company leverages precision medicine and nanoparticle technology to maximize the potential of mTOR inhibition, aiming to offer transformative therapies to cancer patients with mTOR pathway driver alterations. Their lead product has received FDA approval for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PEComa). Aadi's leadership team consists of industry veterans from top biotech companies with a track record of bringing novel cancer therapies to market. The company's science-first mindset and patient-centric approach align with its commitment to developing products for cancers with mTOR pathway driver alterations. Founded in 2011, Aadi Bioscience is headquartered in the United States. The company recently received a $72.50M Post-IPO Equity investment on 22 September 2022 from notable investors including Acuta Capital, Avoro Capital, KVP Capital, Alerce Medical Technology Partners, and Acorn Capital Advisors. For more information, please visit Aadi Bioscience.

Business keywords: biopharmaceutical, precision therapy, mTOR inhibition, genetically-defined cancers, nanoparticle technology, FDA-approved drug, PEComa, cancer therapy, leadership team, precision medicine, patient-centric approach, mTOR pathway, oncology, clinical development, precision oncology

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $72.50M 5
Avoro Capital Acorn Capital Advisors
Avoro Capital, Acorn Capital Advisors +3
22 Sep 2022
Post IPO Equity $155.00M 5
Vivo Capital Acorn Bioventures Rock Springs Capital
Vivo Capital, Acorn Bioventures +3
26 Aug 2021
Series A $23.00M -
08 May 2017

Aadi Bioscience, Inc Alternatives & Competitors

View All Alternatives
Aadi Bioscience, Inc vs
SpringWorks Therapeutics
SpringWorks Therapeutics United States

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach t...

Post-IPO Equity
372 employees
Biopharma, Biotechnology
Aadi Bioscience, Inc vs
Avelos Therapeutics
Avelos Therapeutics Korea South

Strive for a Better Tomorrow.

Series B
9 employees
Biotechnology, Life Sciences
Aadi Bioscience, Inc vs
ORIC Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc. United States

Overcoming Resistance In Cancer

Post-IPO Equity
119 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Aadi Bioscience, Inc

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers.
Aadi Bioscience, Inc was founded in 2011.
Aadi Bioscience, Inc is headquartered in Los Angeles, United States.
Aadi Bioscience, Inc operates in Biopharma, Biotechnology and Life Sciences. Its work centres on biopharmaceutical, precision therapy, mTOR inhibition and genetically-defined cancers.
Aadi Bioscience, Inc has approximately 69 employees.
Aadi Bioscience, Inc has completed 3 funding rounds, raising a total of $250.50M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Aadi Bioscience, Inc include SpringWorks Therapeutics, Avelos Therapeutics, ORIC Pharmaceuticals Inc., Arno Therapeutics Inc (ARNI), Nexo Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aadi Bioscience, Inc and SpringWorks Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Aadi Bioscience, Inc, https://bouncewatch.com/company/aadi-bioscience-inc, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes